Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics' stock (ARTV) has experienced volatility with a 52-week trading range between $1.47 and $7.36. On November 12, 2025, the stock gained 10.86% after announcing its third-quarter 2025 financial results and the FDA granting Fast Track Designation to AlloNK for refractory rheumatoid arthritis. As of February 7, 2026, the stock was trading around $4.03, with analysts having an average 12-month price target of $17.00 and a "Strong Buy" rating. The next earnings report is expected on March 29, 2026.

There is no explicit information available indicating demand seasonality for Artiva Biotherapeutics' products or services. Demand is primarily driven by clinical trial progress, regulatory approvals, and the medical need for effective treatments.

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company in the Healthcare sector and Biotechnology industry, focused on developing allogeneic natural killer (NK) cell-based therapies for autoimmune diseases and cancers. Its core business revolves around advancing a pipeline of "off-the-shelf" allogeneic NK cell therapies, including AlloNK (AB-101) for autoimmune diseases and B-cell non-Hodgkin lymphoma, AB-201 for solid tumors, AB-205 for hematological malignancies, and AB-301 (On-Demand NK Cell Therapy Platform) for developing on-demand, allogeneic NK cell therapies.

Artiva Biotherapeutics is headquartered in San Diego, California, and has a strategic partnership with GC Cell in the Republic of Korea. This partnership grants Artiva exclusive worldwide rights (excluding Asia, Australia, and New Zealand) to GC Cell's NK cell manufacturing technology and programs.

Artiva Biotherapeutics' brand reputation has been positively impacted by the FDA granting Fast Track Designation to AlloNK for refractory rheumatoid arthritis in October 2025. Upcoming presentations at the 2026 Transplantation & Cellular Therapy Meetings and data readouts in the first half of 2026 for AlloNK in refractory RA are anticipated to further enhance its reputation.

Artiva Biotherapeutics has 67 institutional owners and shareholders holding a total of 18,762,467 shares, including major shareholders like Ra Capital Management, L.p., 5AM Venture Management, LLC, and VR Adviser, LLC. Fred Aslan, the President, CEO, and Director, has engaged in multiple "Sell" transactions of company shares between August and December 2025.